Skip to content

Evaluation of the effect of Empagliflozin on blood glucose, BMI, HbA1c and insulin dose in patients with type 1 diabetes

Evaluation of the effect of Empagliflozin on blood glucose, BMI, HbA1c and insulin dose in patients with type 1 diabetes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130610013612N12
Enrollment
60
Registered
2022-09-12
Start date
2022-08-22
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 1. Type 1 diabetes mellitus

Interventions

Intervention 1: Control group: the control group individuals will receive starch tablets which are completely identical in appearance to the supplement and will receive daily for 3 months. Interventi

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Type 1 diabetes Age over 18 years and less than 30 years Able to measure blood sugar daily Be able to measure daily urine ketones HbA1C between 7.5% - 8.5%

Exclusion criteria

Exclusion criteria: Kidney failure Active infection urinary infection pregnancy Cortone use

Design outcomes

Primary

MeasureTime frame
Hemoglobin A1c. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Fasting Blood Sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;2 hour Post Prandial. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: weight scale and stadiometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Najafipour

Tabriz University of Medical Sciences

najafipourf@tbzmed.ac.ir+98 41 3334 8939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026